Diabetic Macular Edema Market Indication Type, Treatment Type, and End User - Analysis and Forecast to 2025
Diabetic Macular Edema Market from Qurate’s Repository provides detailed information, in-depth analysis, and forecast which is developed by a team of experts and professionals
(EMAILWIRE.COM, August 16, 2018 ) Industry Trend Analysis
The global diabetic macular edema (DME) market is expected to be around 4 billion by 2025. Some of the key factors driving this market are high prevalence of diabetic retinopathy and diabetic macular edema and increasing prevalence of geriatric population around the world. According to the National Center for biotechnology Information, DME is expected to affect around 592 million people by 2035. With such high incidence of DME, the demand for therapies to treat DME is expected to considerably increase during the forecast period. Older adults are more susceptible to diabetes. With increasing prevalence of older population globally, the risk of DME is also expected to increase during the forecast period.
Request for Free Sample@ https://www.qurateresearch.com/report/sample/HnM/QBI-CMR-HnM-54971
Indication Type Outlook and Trend Analysis
Based on the indication type, the global diabetic macular edema market is segmented into diffuse diabetic macular edema and focal diabetic macular edema. Focal macular edema is caused due to leakage from microaneurysms which results in hard exudate rings. It is caused due to foci of vascular abnormalities which are associated with an abnormally high permeability. Diffused macular edema is caused due to dilated retinal capillaries. It is a result of leakage from arterioles, capillaries and microaneurysms.
Treatment Type Outlook and Trend Analysis
Corticosteroid therapy can be used to treat patients suffering from recurrent or advanced DME. Corticosteroids are anti-inflammatory non-specific agents and can be effective when administered intravitreally. Grid laser photocoagulation is a standard therapy used for treatment of DME. The laser is applied in a grid-like pattern in order to clear scars that lead to vision loss and blind spots and to destroy the damaged tissue. Implants filled with drugs are also widely used for treating patients with DME caused due to retinal vein occlusion which is one of the common causes leading to macular edema.
Regional Outlook and Trend Analysis
North America held a substantial share of the global DME market in 2016 owing to high prevalence of diabetes, high awareness among people about DME and the available treatment options and better reimbursement policies in the region. The region is expected to maintain its dominance over the market during the forecast period. European DME market is expected to show lucrative growth during the forecast period owing to presence of large patient pool in the region.
Competitive Analysis
The key strategy followed by the players operating in the global DME market is product development. These players develop advanced products and therapies to effectively treat recurring or advanced DME and in turn, occupy a larger share of the market. For instance, in February 2015, Genentech, Inc., a subsidiary of the Roche group obtained FDA approval for their Lucentis (ranibizumab injection) 0.3 mg for treating diabetic retinopathy in patients affected by DME. It is administered as an injection by a physician once a month. Some of the key players operating in this market are, Bayer AG, F. Hoffmann-La Roche Ltd., Alimera Sciences, Inc., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Allergan plc, Novartis AG and Bausch & Lomb Incorporated (acquired by Valeant Pharmaceuticals International, Inc.).
Customize Now@ https://www.qurateresearch.com/report/customize/HnM/QBI-CMR-HnM-54971
Diabetic Macular Edema Market Segmentation:
By Indication Type:
Diffuse Diabetic Macular Edema
Focal Diabetic Macular Edema
By Treatment Type:
Corticosteroid Therapy
Grid Laser Photocoagulation
Implants
Anti-vascular Endothelial Growth Factor Therapy
Focal Laser Treatment
By End User:
Ophthalmic Clinics
Hospitals
Ambulatory Surgical Centers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Russia
Italy
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific
South America
Brazil
Argentina
Columbia
Rest of South America
Middle East and Africa
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Click on the link to Buy Now@ https://www.qurateresearch.com/report/buy/HnM/QBI-CMR-HnM-54971
The global diabetic macular edema (DME) market is expected to be around 4 billion by 2025. Some of the key factors driving this market are high prevalence of diabetic retinopathy and diabetic macular edema and increasing prevalence of geriatric population around the world. According to the National Center for biotechnology Information, DME is expected to affect around 592 million people by 2035. With such high incidence of DME, the demand for therapies to treat DME is expected to considerably increase during the forecast period. Older adults are more susceptible to diabetes. With increasing prevalence of older population globally, the risk of DME is also expected to increase during the forecast period.
Request for Free Sample@ https://www.qurateresearch.com/report/sample/HnM/QBI-CMR-HnM-54971
Indication Type Outlook and Trend Analysis
Based on the indication type, the global diabetic macular edema market is segmented into diffuse diabetic macular edema and focal diabetic macular edema. Focal macular edema is caused due to leakage from microaneurysms which results in hard exudate rings. It is caused due to foci of vascular abnormalities which are associated with an abnormally high permeability. Diffused macular edema is caused due to dilated retinal capillaries. It is a result of leakage from arterioles, capillaries and microaneurysms.
Treatment Type Outlook and Trend Analysis
Corticosteroid therapy can be used to treat patients suffering from recurrent or advanced DME. Corticosteroids are anti-inflammatory non-specific agents and can be effective when administered intravitreally. Grid laser photocoagulation is a standard therapy used for treatment of DME. The laser is applied in a grid-like pattern in order to clear scars that lead to vision loss and blind spots and to destroy the damaged tissue. Implants filled with drugs are also widely used for treating patients with DME caused due to retinal vein occlusion which is one of the common causes leading to macular edema.
Regional Outlook and Trend Analysis
North America held a substantial share of the global DME market in 2016 owing to high prevalence of diabetes, high awareness among people about DME and the available treatment options and better reimbursement policies in the region. The region is expected to maintain its dominance over the market during the forecast period. European DME market is expected to show lucrative growth during the forecast period owing to presence of large patient pool in the region.
Competitive Analysis
The key strategy followed by the players operating in the global DME market is product development. These players develop advanced products and therapies to effectively treat recurring or advanced DME and in turn, occupy a larger share of the market. For instance, in February 2015, Genentech, Inc., a subsidiary of the Roche group obtained FDA approval for their Lucentis (ranibizumab injection) 0.3 mg for treating diabetic retinopathy in patients affected by DME. It is administered as an injection by a physician once a month. Some of the key players operating in this market are, Bayer AG, F. Hoffmann-La Roche Ltd., Alimera Sciences, Inc., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Allergan plc, Novartis AG and Bausch & Lomb Incorporated (acquired by Valeant Pharmaceuticals International, Inc.).
Customize Now@ https://www.qurateresearch.com/report/customize/HnM/QBI-CMR-HnM-54971
Diabetic Macular Edema Market Segmentation:
By Indication Type:
Diffuse Diabetic Macular Edema
Focal Diabetic Macular Edema
By Treatment Type:
Corticosteroid Therapy
Grid Laser Photocoagulation
Implants
Anti-vascular Endothelial Growth Factor Therapy
Focal Laser Treatment
By End User:
Ophthalmic Clinics
Hospitals
Ambulatory Surgical Centers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Russia
Italy
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific
South America
Brazil
Argentina
Columbia
Rest of South America
Middle East and Africa
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Click on the link to Buy Now@ https://www.qurateresearch.com/report/buy/HnM/QBI-CMR-HnM-54971
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results